How Shares Look in the Eyes of Analysts: Fitbit Inc (NYSE:FIT), Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), Union Pacific Corporation (NYSE:UNP)

According to data provided by Zacks Research, Fitbit Inc (NYSE:FIT) has a consensus target price of $9.357 on the stock. Out of the polled analysts providing targets, the high is currently $21, while the low is resting at $5. Analyst price targets may vary depending on the individual method used to calculate the estimate.
Turning to earnings, analysts are expecting Fitbit Inc (NYSE:FIT) to post a current quarter EPS of $-0.25. This consensus number is compiled by Zacks Research. For the period ending on 2016-12-31, the company reported EPS for the quarter of $-0.63. The resulting surprise factor from the difference between the reported number and the consensus estimate going into earnings was -3.28%. After a company reports earnings, the stock may see increased activity. The next earnings report date is scheduled on or near 2017-05-03.
In terms of analyst ratings, Fitbit Inc (NYSE:FIT) has a current ABR of 2.94. This average broker recommendation is given by Zacks using a scale from 1 to 5. According to this scale, a rating of 1 or 2 would indicate a Buy, and a rating of 4 or 5 would signify a Sell recommendation. A 3 would indicate a Hold on the stock.

According to data provided by Zacks Research, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has a consensus target price of $427.214 on the stock. Out of the polled analysts providing targets, the high is currently $598, while the low is resting at $350. Analyst price targets may vary depending on the individual method used to calculate the estimate.
Turning to earnings, analysts are expecting Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to post a current quarter EPS of $2.5. This consensus number is compiled by Zacks Research. For the period ending on 2016-12-31, the company reported EPS for the quarter of $2.19. The resulting surprise factor from the difference between the reported number and the consensus estimate going into earnings was -12.75%. After a company reports earnings, the stock may see increased activity. The next earnings report date is scheduled on or near 2017-05-04.
In terms of analyst ratings, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has a current ABR of 2.22. This average broker recommendation is given by Zacks using a scale from 1 to 5. According to this scale, a rating of 1 or 2 would indicate a Buy, and a rating of 4 or 5 would signify a Sell recommendation. A 3 would indicate a Hold on the stock.

The Wall Street analysts who cover Union Pacific Corporation (NYSE:UNP) shares are providing price target projections on the company. They project that the shares will move to $106.294 within the upcoming year. The number they've arrived at is calculated by Zacks.com, long known as a provider of top-notch investment research. From the analysts polled by Zack's Research, the highest estimate stands at $126 and the lowest is at $53 for the stock. This number may be different from what First Call has published for the consensus target estimate. Analysts that routinely cover the company may use varying techniques in order to create a future target price. Because of the different methods that analysts can use, targets may differ greatly between analysts.

Analyst Ratings In View

Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for institutions and retail investors alike. This the calculated average of the actual recommendations (strong buy, hold, sell etc.) made for a given stock. The ABR is typically displayed with decimals (e.g. 1.52) versus the Zacks Rank, which is only shown in whole numbers (e.g. 1, 2, 3, etc.). This simplifies brokerage recommendations, which can become complicated. Union Pacific Corporation (NYSE:UNP)'s shares currently have an ABR of 2.36. A 1 rating would point to a Strong Buy, and a score of 5 would signify a Strong Sell rating. The average broker rating assists investors by providing them with a general feel for analyst sentiment on company shares.  The success of analyst predictions can be tracked for institutional investors through First Call.  Retail investors can use tools such as TipRanks or Marketbeat in order to track analyst performance. 

During this fiscal period, Street analysts are projecting $1.22 earnings/share. This represents the current Zacks consensus EPS. For the period which closed on 2016-12-31, Union Pacific Corporation (NYSE:UNP) dialed in an EPS of $1.39, creating a Surprise Factor of 3.73% (the difference between analyst projections and actual numbers). Curious investors will be awaiting 2017-04-20, the date when Union Pacific Corporation (NYSE:UNP) will release their quarterly results.  A surprise factor in either direction may result in significant stock movement immediately and in the days following the release.  Firms that consistently miss expectations can experience a downtrend over time.  Whereas stocks that consistently outperform analyst expectations, can often see positive stock movement. 

Leave a Comment